China Health Industries Holdings, Inc.

China Health Industries Holdings, Inc., through its subsidiaries, manufactures and sells health products. It offers hemp derivative products, such as hemp oil, hemp protein powder, hemp polypeptides, collagen peptides, hemp essence repair lotions, hemp revitalizing essence products, hemp anti-aging brightening eye creams, and hemp frozen age nourishing creams. The company also provides health supplements, including Sailuozhi soft capsule, which is made from frog oil, soybean isoflavone, procyanidine, and vitamin E for freckle removal and skin moisture supplements under the QunLe brand; and propolis and black ant capsule that is made from propolis, black ant, acanthopanax, and astragalus root under the Kindlink brand. In addition, it offers health products for acne removal, relieving eyestrain, enhancing bone density, enhancing memory, enhancing nutritional anemia and chloasma, relaxing bowels and promoting the discharge of lead, enhancing immunity and relieving physical fatigue, and dispelling chloasma, as well as iron and multivitamin, and mineral supplements. Further, the company manufactures and sells various types of medical drugs. It primarily sells its products through sales agents. China Health Industries Holdings, Inc. is based in Harbin City, the People's Republic of China.

China Health Industries Holdings, Inc. trades as CHHE on OTC. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in USD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $111,579 of revenue and -$409,000 of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

China Health Industries Holdings, Inc. can be compared against peers such as BioQuest Corp., Eco-Growth Strategies Inc., Herbal Dispatch Inc., Medicure Inc., Noveris Health Sciences Inc., Numinus Wellness Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $6,554, beta of -20.54, and return on equity of -1.0%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

CHHE currently shows total debt of $5.15M and beta of -20.54. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: NT 10-Q (2025-02-14 00:00:00), NT 10-Q (2024-11-14 00:00:00), NT 10-K (2024-09-30 00:00:00), 8-K (2024-09-13 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.chinahealthindustries.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.